TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT ...

Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...

These pose a health risk to the public. Sahpra cautions the public to not purchase and/or consume such products as their ...

SAHPRA cautions the public to not purchase and/or consume such products as their safety, efficacy, and quality have not been ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

By August 2024, that number had risen nearly tenfold to more than 1.8 million monthly approved claims. This data currently ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...